Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Literature
1.
2.
Sandal R, Jandial A, Mishra K, Lad D, Prakash G, Khadwal A (2018) Real world experience of generic carfilzomib for relapsed refractory multiple myeloma (RRMM). Indian J Hematol Blood Transfus 34(Suppl 1):372
3.
4.
Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S et al (2018) Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 378(6):518–528CrossRefPubMed
5.
Jakubowiak Andrzej J, Chari Ajai, Lonial Sagar, Weiss Brendan M, Comenzo Raymond L, Kaida Wu et al (2017) Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): an open-label, phase 1b study. J Clin Oncol 35:8000CrossRef
6.
Voorhees PM, Rodriguez C, Reeves B, Nathwani N, Costa LJ, Lutska Y et al (2018) Efficacy and updated safety analysis of a safety run-in cohort from griffin, a phase 2 randomized study of daratumumab (Dara), bortezomib (V), lenalidomide (R), and dexamethasone (D; Dara‐Vrd) vs. Vrd in patients (Pts) with newly diagnosed (ND) multiple myeloma (MM) eligible for high‐dose therapy (HDT) and autologous stem cell transplantation (ASCT). Blood 132(Suppl 1):151.
7.
DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al (2009) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113(23):5720–5726PubMed
8.
Wallis WD, Qazilbash MH (2017) Peripheral blood stem cell mobilization in multiple myeloma: growth factors or chemotherapy? World J Transplant 7(5):250–259CrossRefPubMedPubMedCentral
9.
Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J et al (2014) Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 20(3):295–308CrossRefPubMed
Metadata
Title
Poor Mobilisation After Daratumumab Based Combination Chemotherapy in Patients of Newly Diagnosed Multiple Myeloma
Authors
Kundan Mishra
Aditya Jandial
Rajeev Sandal
Deepesh Lad
Gaurav Prakash
Alka Khadwal
Pankaj Malhotra
Publication date
01-07-2019
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 3/2019
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-019-01135-4

Other articles of this Issue 3/2019

Indian Journal of Hematology and Blood Transfusion 3/2019 Go to the issue

Correspondence

Rechallenging to Hydroxycarbamide Post Thalidomide Treatment and Response in a Non Transfusion-Dependent Patient, is it Possible?

Short Communication

Obituary: Professor Sir David John Weatherall GBE, MD, FRCP, FRS

Original Article

Haploidentical Stem Cell Transplantation in Children with Benign Disorders: Improved Survival and Cost-Effective Care Over 15 Years from a Single Center in India

Original Article

Evaluation of Coagulation Factors Activity in Different Types of Plasma Preparations

Original Article

Detection of EBV DNA in Non-Hodgkin Lymphoma Patients in Bulgaria

Short Communication

Review of the Abstracts on Advances in Transfusion Medicine at Hematocon 2018
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits